SCHEMBL12230253

SCHEMBL12230253

N#Cc1ccc(NS(=O)(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.67
PGR P06401 2/20 0.63
BRD1 O95696 2/20 0.62
BRPF1 P55201 2/20 0.62
BRPF3 Q9ULD4 2/20 0.62
LMNA P02545 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
ALDH1A1 P00352 2/20 0.60
CYP19A1 P11511 1/20 0.60
GAA P10253 1/20 0.60
PKM P14618 1/20 0.59
PKLR P30613 1/20 0.59
AR P10275 1/20 0.59
KAT6A Q92794 1/20 0.56
AKT1 P31749 1/20 0.56
KDM4E B2RXH2 1/20 0.56
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
MAPT P10636 1/20 0.55
BRD4 O60885 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28316252 0.94 LMNA (0.69) ATMPGRBRD1BRPF1BRPF3
SCHEMBL852159 0.86 PRSS1 (0.65) ATMPGRBRD1BRPF1BRPF3
SCHEMBL28396503 0.82 PGR (0.77) ATMPGRBRD1BRPF1LMNA
SCHEMBL29549847 0.82 PGR (0.77) ATMPGRBRD1BRPF1LMNA
SCHEMBL20021987 0.82 PGR (0.77) ATMPGRBRD1BRPF1LMNA
SCHEMBL14645822 0.81 CYP19A1 (0.75) ALDH1A1CYP19A1GAAPKMAR
SCHEMBL7572258 0.81 CYP19A1 (0.75) PGRALDH1A1CYP19A1PKMAR
SCHEMBL7572129 0.80 GLO1 (0.60) BRD1BRPF1BRPF3CYP19A1AR
SCHEMBL808105 0.80 ATM (0.72) ATMPGRLMNASMN1; SMN2ALDH1A1
SCHEMBL9942088 0.80 ATM (0.72) ATMPGRLMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9566284-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2017-02-14 US disclosed
US-20140235619-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO INC. (CA) 2014-08-21 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES TRPM7, TRPM8, TRPM6 ATM 1792/4885PGR 4448/4885BRD1 3483/4885
US-20140235619-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES TRPM7, TRPM8, TRPM6 ATM 1792/4885PGR 4448/4885BRD1 3483/4885
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 ATM 2475/4885PGR 3698/4885BRD1 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.